D. E. Shaw & Co. Inc. Reduces Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

D. E. Shaw & Co. Inc. trimmed its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 14.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 140,104 shares of the company's stock after selling 23,603 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.28% of Prestige Consumer Healthcare worth $10,941,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Kestra Investment Management LLC purchased a new stake in Prestige Consumer Healthcare in the 4th quarter valued at approximately $27,000. CIBC Private Wealth Group LLC boosted its stake in shares of Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after acquiring an additional 152 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Prestige Consumer Healthcare during the 4th quarter worth about $40,000. Johnson Financial Group Inc. purchased a new stake in Prestige Consumer Healthcare during the 4th quarter worth about $93,000. Finally, Huntington National Bank raised its stake in Prestige Consumer Healthcare by 133.2% in the 4th quarter. Huntington National Bank now owns 1,481 shares of the company's stock valued at $116,000 after purchasing an additional 846 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Trading Down 0.3%

Shares of NYSE:PBH traded down $0.29 during trading on Tuesday, reaching $88.65. 61,978 shares of the stock were exchanged, compared to its average volume of 294,128. The firm's 50-day moving average price is $83.37 and its 200 day moving average price is $82.04. The firm has a market cap of $4.38 billion, a price-to-earnings ratio of 20.74, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $90.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.02. The firm had revenue of $296.52 million during the quarter, compared to the consensus estimate of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The firm's quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.02 EPS. On average, sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PBH has been the subject of a number of analyst reports. Canaccord Genuity Group boosted their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Royal Bank of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday. DA Davidson increased their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Finally, Oppenheimer raised their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare has an average rating of "Moderate Buy" and an average target price of $93.33.

Insider Activity at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the sale, the senior vice president now owns 17,157 shares in the company, valued at $1,544,130. This trade represents a 8.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.60% of the company's stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.